Limits...
The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis.

Wang F, Zhou J, Zhang Y, Wang Y, Cheng L, Bai Y, Ma H - PLoS ONE (2015)

Bottom Line: The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated.A total of 6 studies were included for this meta-analysis.For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou province, China.

ABSTRACT

Background: Recent studies have shown that miR-155 play a positive role in the development of carcinoma. This meta-analysis aimed to identify the role of miR-155 in the survival of non-small cell lung cancer patients.

Methodology: Eligible studies were identified through database searches. Relevant data were extracted from each eligible study to assess the correlation between miR-155 expression and survival in lung carcinoma patients. The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated. A total of 6 studies were included for this meta-analysis. For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant. Additionally, in Asian and America subgroups, greater expression levels of miR-155 were related to poor prognoses for lung cancer (HR 1.71 95% CI: 1.22-2.40, P = 0.002, HR 2.35 95% CI: 1.42-3.89 P = 0.001), while no significant relationship was present in a Europe subgroup (HR 0.75 95%CI: 0.27-2.10, P = 0.587).

Conclusions: These results suggest that miR-155 expression is not significantly related to non-small cell lung cancer patients except in patients from Asian and America.

No MeSH data available.


Related in: MedlinePlus

Evaluations of the qualities of the included studies based on the Newcastle-Ottawa Scale.Each band shows the percentage of the six studies with different numbers of stars.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556438&req=5

pone.0136889.g001: Evaluations of the qualities of the included studies based on the Newcastle-Ottawa Scale.Each band shows the percentage of the six studies with different numbers of stars.

Mentions: We assessed the quality of all of the studies included with the Newcastle-Ottawa scale (NOS) for the quality of cohort studies[17]. Two investigators independently performed the quality assessments. The NOS contains three categories (selection, comparability, and outcome) and eight items. In the selection and outcome categories, a quality research item received one star, and a comparable category could receive at most two stars. In the selection part, studies that precisely described the item (i.e., those drawn from the same community as the exposed cohort with secure records and a demonstration that outcome of interest was not present at start of the study) received one star. Regarding comparability, two items (i.e., study controls as the most important factor, and study controls as an additional factor) could receive a star if the study was eligible. In the outcome portion, various items (i.e., outcome assessments, a follow-up that was sufficiently long for outcomes to occur, and adequate follow up of cohorts) could elicit one star each if the study presented the corresponding details. The quality assessment values ranged from 0 to 9 stars (S1 Table). Each band in Fig 1 indicates the percentage of the six studies that met each of these quality criteria.


The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis.

Wang F, Zhou J, Zhang Y, Wang Y, Cheng L, Bai Y, Ma H - PLoS ONE (2015)

Evaluations of the qualities of the included studies based on the Newcastle-Ottawa Scale.Each band shows the percentage of the six studies with different numbers of stars.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556438&req=5

pone.0136889.g001: Evaluations of the qualities of the included studies based on the Newcastle-Ottawa Scale.Each band shows the percentage of the six studies with different numbers of stars.
Mentions: We assessed the quality of all of the studies included with the Newcastle-Ottawa scale (NOS) for the quality of cohort studies[17]. Two investigators independently performed the quality assessments. The NOS contains three categories (selection, comparability, and outcome) and eight items. In the selection and outcome categories, a quality research item received one star, and a comparable category could receive at most two stars. In the selection part, studies that precisely described the item (i.e., those drawn from the same community as the exposed cohort with secure records and a demonstration that outcome of interest was not present at start of the study) received one star. Regarding comparability, two items (i.e., study controls as the most important factor, and study controls as an additional factor) could receive a star if the study was eligible. In the outcome portion, various items (i.e., outcome assessments, a follow-up that was sufficiently long for outcomes to occur, and adequate follow up of cohorts) could elicit one star each if the study presented the corresponding details. The quality assessment values ranged from 0 to 9 stars (S1 Table). Each band in Fig 1 indicates the percentage of the six studies that met each of these quality criteria.

Bottom Line: The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated.A total of 6 studies were included for this meta-analysis.For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou province, China.

ABSTRACT

Background: Recent studies have shown that miR-155 play a positive role in the development of carcinoma. This meta-analysis aimed to identify the role of miR-155 in the survival of non-small cell lung cancer patients.

Methodology: Eligible studies were identified through database searches. Relevant data were extracted from each eligible study to assess the correlation between miR-155 expression and survival in lung carcinoma patients. The hazard ratios (HRs) and 95% confidence intervals (CIs) of the patients' outcomes in relation to miR-155 were calculated. A total of 6 studies were included for this meta-analysis. For overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and cancer-specific survival (CSS), the combined HRs and 95% CIs were not statistically significant. Additionally, in Asian and America subgroups, greater expression levels of miR-155 were related to poor prognoses for lung cancer (HR 1.71 95% CI: 1.22-2.40, P = 0.002, HR 2.35 95% CI: 1.42-3.89 P = 0.001), while no significant relationship was present in a Europe subgroup (HR 0.75 95%CI: 0.27-2.10, P = 0.587).

Conclusions: These results suggest that miR-155 expression is not significantly related to non-small cell lung cancer patients except in patients from Asian and America.

No MeSH data available.


Related in: MedlinePlus